Search

Your search keyword '"Gilbertson, Michael"' showing total 450 results

Search Constraints

Start Over You searched for: Author "Gilbertson, Michael" Remove constraint Author: "Gilbertson, Michael"
450 results on '"Gilbertson, Michael"'

Search Results

51. Assessment and management of newly diagnosed classical Hodgkin lymphoma: a consensus practice statement from the Australasian Lymphoma Alliance

52. Real-World Outcomes of Patients with Primary CNS Lymphoma (PCNSL): A Report from the Australasian Lymphoma Alliance (ALA)

53. High-Dose Methotrexate Is Not Associated with Reduction in CNS Relapse in Patients with Aggressive B-Cell Lymphoma: An International Retrospective Study of 2300 High-Risk Patients

54. Real-World Outcomes of Aggressive B-Cell Non-Hodgkin Lymphoma in People Living with HIV (PLWH) Treated in Australia: An Australasian Lymphoma Alliance Study

55. Promising Real World Survival Data in Adult-Onset Langerhans Cell Histiocytosis: An Australasian Lymphoma Alliance 20 Year Retrospective Study

60. Tislelizumab, an Anti-PD1 Antibody, in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma in Tirhol Bgb-A317-210: A Prospective Multicenter Lysa Phase 2 Study Conducted in Western Countries

61. Optimizing Immunoglobulin Replacement Therapy for Patients with B-Cell Malignancies and Hypogammaglobulinemia: The Investigator-Initiated, International, Randomized Phase II/III Rational Platform Trial, and the Rationalise (STOP IgRT) Domain

62. Disseminated enteroviral infection associated with obinutuzumab

63. WELCOME HOME: How our school district supports English learners.

65. Immune priming with nivolumab followed by nivolumab and rituximab in first-line treatment of follicular lymphoma: The phase 2 1st FLOR study.

72. Excellent outcomes of transformed lymphomas in the rituximab era without autologous stem cell transplantation: an Australian, single‐centre experience

74. Occupation and Breast Cancer: A Canadian Case–Control Study

78. Excellent outcomes of transformed lymphomas in the rituximab era without autologous stem cell transplantation: an Australian single-centre experience.

84. Breast cancer risk in relation to occupations with exposure to carcinogens and endocrine disruptors: a Canadian case–control study

85. Immune Priming with Single-Agent Nivolumab Followed By Combined Nivolumab & Rituximab Is Safe and Efficacious for First-Line Treatment of Follicular Lymphoma; Interim Analysis of the '1st FLOR' Study

86. A multicenter retrospective comparison of induction chemoimmunotherapy regimens on outcomes in transplant‐eligible patients with previously untreated mantle cell lymphoma

88. Preface

91. Outcomes of Stage I and II Follicular Lymphoma in the Era of 18F-FDG PET-CT Staging: An International Collaborative Study from the Australian Lymphoma Alliance

93. Bortezomib plus EPOCH is effective as frontline treatment in patients with plasmablastic lymphoma

96. Bortezomib plus EPOCH is effective as frontline treatment in patients with plasmablastic lymphoma.

97. Causality Advocacy: Workers' Compensation Cases as Resources for Identifying and Preventing Diseases of Modernity.

100. An International Collaborative Study of Outcome and Prognostic Factors in Patients with Secondary CNS Involvement By Diffuse Large B-Cell Lymphoma

Catalog

Books, media, physical & digital resources